<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34510973</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-030X</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Palliative medicine</Title><ISOAbbreviation>Palliat Med</ISOAbbreviation></Journal><ArticleTitle>Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report.</ArticleTitle><Pagination><StartPage>208</StartPage><EndPage>211</EndPage><MedlinePgn>208-211</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/02692163211045314</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuropathic symptoms have a wide variety of manifestations, ranging from pain to pruritus. Neuropathic pruritus is a type of chronic pruritus related to damaged small fibers. Cannabinoids have evidence to manage neuropathic symptoms. We present a case of refractory neuropathic pruritus that was successfully managed with the use of oral cannabinoids.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 60-year-old male with amyotrophic lateral sclerosis with ongoing pruritus despite the use of standard neuropathic therapies.</AbstractText><AbstractText Label="POSSIBLE COURSE OF ACTION" NlmCategory="UNASSIGNED">Sodium channel and <i>N</i>-methyl-D-aspartate receptor antagonists have evidence for neuropathic symptoms but can cause significant gastrointestinal side effects. Prescription cannabinoids such as nabiximol can be cost prohibitive to use in practice. Synthetic tetrahydrocannabinol products are dose limited by psychoactive side effects.</AbstractText><AbstractText Label="FORMULATION OF A PLAN" NlmCategory="UNASSIGNED">A balanced oral cannabinoid from a licensed producer was preferred as it has evidence for neuropathic symptoms and is generally well tolerated.</AbstractText><AbstractText Label="OUTCOME" NlmCategory="RESULTS">The patient showed improvement to his pruritus score from 7/10 to 3/10. There was initial increased sedation but tolerance developed quickly.</AbstractText><AbstractText Label="LESSONS LEARNED FROM CASE" NlmCategory="UNASSIGNED">Cannabinoids are possibly safe and effective in management of neuropathic pruritus.</AbstractText><AbstractText Label="VIEW ON RESEARCH PROBLEMS" NlmCategory="UNASSIGNED">Additional research is needed to establish efficacy and safety.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Kelvin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5922-0161</Identifier><AffiliationInfo><Affiliation>Palliative Medicine, The University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Shane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Palliative Medicine, The University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Palliative Medicine, The University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Palliat Med</MedlineTA><NlmUniqueID>8704926</NlmUniqueID><ISSNLinking>0269-2163</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002186">Cannabinoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>7J8897W37S</RegistryNumber><NameOfSubstance UI="D013759">Dronabinol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002186" MajorTopicYN="Y">Cannabinoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013759" MajorTopicYN="N">Dronabinol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011537" MajorTopicYN="N">Pruritus</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Cannabis</Keyword><Keyword MajorTopicYN="Y">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="Y">cannabinoids</Keyword><Keyword MajorTopicYN="Y">small fiber neuropathy</Keyword></KeywordList><CoiStatement><b>Declaration of conflicting interests:</b> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>13</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34510973</ArticleId><ArticleId IdType="pmc">PMC8796147</ArticleId><ArticleId IdType="doi">10.1177/02692163211045314</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brenaut E, Marcorelles P, Genestet S, et al.. Pruritus: an under recognized symptom of small-fiber neuropathies. J Am Acad Dermatol 2015; 72(2): 328&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">25484269</ArticleId></ArticleIdList></Reference><Reference><Citation>Oaklander AL. Neuropathic itch. In: Carstens E, Akiyama T. (eds) Itch: mechanisms and treatment. Frontiers in neuroscience. Boca Raton, FL: CRC Press/Taylor &amp; Francis, 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">24830000</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalla Bella E, Lombardi R, Porretta-Serapiglia C, et al.. Amyotrophic lateral sclerosis causes small fiber pathology. Eur J Neurol 2016; 23(2): 416&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">26806218</ArticleId></ArticleIdList></Reference><Reference><Citation>Attal N, Cruccu G, Baron R, et al.. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17(9): 1113&#x2013;e88.</Citation><ArticleIdList><ArticleId IdType="pubmed">20402746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sihota A, Smith BK, Ahmed S-A, et al.. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int J Clin Pract 2021; 75: e13871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8365704</ArticleId><ArticleId IdType="pubmed">33249713</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright P, Walsh Z, Margolese S, et al.. Canadian clinical practice guidelines for the use of plant-based cannabis and cannabinoid-based products in the management of chronic non-cancer pain and co-occurring conditions: protocol for a systematic literature review. BMJ Open 2020; 10(5): e036114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7253000</ArticleId><ArticleId IdType="pubmed">32448797</ArticleId></ArticleIdList></Reference><Reference><Citation>MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med 2018; 49: 12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">29307505</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan GM, Ramji J, Perry D, et al.. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician 2018; 64(2): 111&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964385</ArticleId><ArticleId IdType="pubmed">29449241</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan GM, Finley CR, Ton J, et al.. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician 2018; 64(2): e78&#x2013;e94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964405</ArticleId><ArticleId IdType="pubmed">29449262</ArticleId></ArticleIdList></Reference><Reference><Citation>
Government of Canada. Licensed cultivators, processors and sellers of cannabis under the Cannabis Act. AEM. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/industry-licensees-applicants/licensed-cultivators-processors-sellers.html (2018, accessed 21 February 2021).</Citation></Reference><Reference><Citation>Groenman AP, Schweren LJ, Dietrich A, et al.. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Saf 2017; 16(4): 455&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">28277842</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>